|Molecular Vision 2006;
Received 31 January 2006 | Accepted 20 July 2006 | Published 6 October 2006
Cannabinoid receptor-mediated inhibition of calcium signaling in rat retinal ganglion cells
Mélanie R. Lalonde,1 Christine A.B Jollimore,2
Kelly Stevens,1 Steven Barnes,1,3
Melanie E.M. Kelly2
Departments of 1Physiology and Biophysics, 2Pharmacology, and 3Ophthalmology and Visual Sciences, Dalhousie University, Halifax, Nova Scotia, Canada
Correspondence to: Melanie E.M. Kelly, PhD., Department of Pharmacology, Dalhousie University, Halifax, Nova Scotia, Canada, B3H 4H7; Phone: 902-494-3325; FAX: (902) 494-6309; email: email@example.com
Purpose: The physiological actions of CB1 cannabinoid receptors (CB1Rs) in mammalian retina have yet to be fully described in all cell types. Here we investigate the actions of CB1R activation on high-voltage-activated (HVA) Ca2+ channel currents in purified cultures of rat retinal ganglion cells (RGCs).
Methods: Reverse transcriptase polymerase chain reaction (RT-PCR) and immunocytochemistry were used to determine the presence of CB1R mRNA and protein in a purified RGC culture generated from neonatal rats using a two-step panning procedure. Ruptured-patch whole-cell voltage clamp was used to test the effect of CB1R agonists (WIN 55,212-2) and antagonists (SR141716A, AM281) on HVA Ca2+ channel currents.
Results: RT-PCR analysis confirmed CB1R mRNA in cultured RGCs and immunocytochemistry for CB1R protein revealed labeling in both the cell body and neurites of isolated RGCs. Patch-clamp recording from cultured rat RGCs showed that the CB1R agonist WIN 55,212-2 inhibited HVA Ca2+ channel currents up to 50% in a concentration-dependent manner (0.5, 1, and 5 μM). The Ca2+ channel current inhibition by WIN 55,212-2 was blocked by CB1R antagonists AM281 and SR141716.
Conclusions: Activation of CB1Rs in cultured RGCs inhibits HVA Ca2+ channel currents. These data show that cannabinoids can modify the excitability of RGCs and could affect retinal output. This finding has implications for retinal signal processing as it suggests that endogenous cannabinoids have inhibitory effects on RGCs and that exogenous cannabinoids could modulate retinal function by this pathway as well.
Cannabinoids, the main psychoactive components of marijuana and hashish, act on endogenous G protein-coupled receptors. Two cannabinoid receptor subtypes have been cloned, CB1R and CB2R, and are activated by endogenous endocannabinoid ligands such as anandamide (N-arachidonoylethanolamide, AEA), 2-arachidonoyl glycerol (2-AG) and 2-arachidonoyl glyceryl ether [1-4]. Evidence that non-CB1/CB2 cannabinoid receptors also contribute to endocannabinoid action in specific tissues has recently emerged .
CB1Rs are conserved among vertebrate species and are abundantly expressed in the mammalian nervous system. CB2Rs are expressed in peripheral tissues, specifically in immune cells , but have also been identified in areas of the brain [7,8] and the eye . CB2R mRNA has been reported in the retina . Both CB1Rs and CB2Rs couple to G proteins of the Gi/o subtype, although coupling to Gs  and Gq  has been reported for the CB1R. Activation of CB1Rs results in inhibition of adenylyl cyclase and a decrease in levels of cAMP  as well as activation of the mitogen activated protein kinase pathway . CB1R activation also has been reported to inhibit both N-type [15-19] and P/Q-type voltage-dependent Ca2+ channels [17,20]. Consistent with the inhibitory effects of cannabinoids on Ca2+ channel currents, several studies have now shown that cannabinoids can reduce the presynaptic release of neurotransmitters, including glutamate [21,22] and inhibit postsynaptic voltage-dependent Ca2+ channels, to modulate neuronal excitability and synaptic transmission .
CB1R immunoreactivity has been detected throughout the retina of a number of species including rat, with immunoreactivity detected in the ganglion cell layer and ganglion cell axons . However, the cellular effects of cannabinoids on RGCs have not been investigated. The aims of the present study were to determine whether CB1Rs are expressed in isolated purified RGC cultures and to determine whether exogenous cannabinoids, acting via CB1Rs, can modulate neuronal Ca2+ signaling via alterations in Ca2+ channel activity.
Reverse transcriptase polymerase chain reaction
All procedures were performed in accordance with the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research and the Dalhousie University Committee for the Use of Laboratory Animals. To obtain RNA, adult Long-Evans rats (Charles River, Montreal, Quebec) were deeply anesthetized using sodium pentobarbital, decapitated, and the eyes enucleated. The anterior segment and lens were removed and discarded. The retina was then dissected out from the posterior eyecups and immersed in liquid nitrogen and stored at -70 °C prior to RNA extraction using TRIZOLTM according to the manufacturer's instructions (Invitrogen). cDNA was obtained from 2 μg of total RNA using random primers, oligo(dt)15-18, and moloney murine leukemia virus (M-MLV) reverse transcriptase (Life Technologies, Burlington, Ontario). The primers for amplification of the CB1R are shown in Table 1. Using cDNA from rat retina as a template, PCR conditions for amplification of the CB1R included: denaturation at 94 °C for 1 min, 35 cycles of denaturation at 94 °C for 30 s, annealing at 65 °C for 1 min and extension at 72 °C for 1 min, followed by final extension at 72 °C for 10 min. PCR products were visualized by 1.0% agarose gel containing ethidium bromide. The amplicons were verified as previously described [25,26], using restriction enzyme analysis as well as sequencing (DNA Sequencing Facility, Dalhousie University).
Coverslips with cultured RGCs were fixed in 4% paraformaldehyde for 2 h at 4 °C. Following fixation, cells were subjected to three 5 min washes with phosphate-buffered solution (PBS) and followed by 20 min incubation with 0.3% Triton X-100. After three additional 5 min washes with PBS, a solution of PBS containing 10% goat serum was applied to the cells for 1.5 h at room temperature. The PBS/goat serum was removed, and the fixed cells were incubated overnight at 4 °C with a fresh solution of PBS containing the primary antibody (1:200; rabbit anti-CB1R; Cayman Chemical Company, Ann Arbor, MI). The next day, the cells were rinsed five times with fresh PBS for 5 min per wash and then incubated with the secondary antibody (1:200; AlexaFluor 546 goat anti-rabbit; Invitrogen Canada Inc., Burlington, Ontario) at room temperature for 1 h. The cells were then washed with distilled water once, followed by three washes in PBS at 5 min per wash, coverslipped and visualized with a 60X oil immersion lens using a laser-scanning confocal microscope (Nikon C1, Nikon Instruments, Mississauga, Ontario). Control experiments were performed, as per the manufacturer's instructions, by preabsorption of the primary antibody with the antigen peptide (1:1) for 1 h with agitation before application to the cells and repeating the staining protocol.
Purified retinal ganglion cell culture
Natural litters (one to ten pups for each experiment) of Long-Evans rats (Charles River, Montreal, Quebec) were sacrificed at postnatal 7 to 8 days by overexposure to halothane and decapitation. Following enucleation, the anterior segment and lens were removed and the posterior eyecups were immersed in dissection medium consisting of Hibernate-A (BrainBits, Springfield, IL) with 2% B27 supplements and 10 μg/ml gentamicin. The retinas were dissected and maintained in the dissection medium until all retinas were isolated.
The retinal tissue was incubated for 30 min at 37 °C in a papain (Worthington Biochemicals, Lakewood, NJ) solution (165 units in 10 ml Ca2+/Mg2+-free DPBS) containing 1 mM L-cysteine and 0.004% DNase. The papain-treated retinas were then triturated sequentially in DPBS (with Ca2+ and Mg2+) containing 1.5 mg/ml ovomucoid (Roche Diagnostics, Laval, Quebec), 1.5 mg/ml bovine serum albumin (BSA), and 0.004% DNase. In addition, this solution contained the rabbit anti-rat macrophage antibodies (1:75; Axell brand, Accurate Chemical, Westbury, NY) for the macrophage-panning step. The suspension was centrifuged, rewashed in a high concentration ovomucoid/BSA solution (10 mg/ml each in DPBS), and the dissociated cells were resuspended in DPBS with 0.2 mg/ml BSA and 5 μg/ml insulin.
The two-step panning procedure to purify the RGCs has been previously described [27-29]. Briefly, macrophages were first removed by incubating the mixed retinal cell suspension on petri dishes coated with affinity-purified goat anti-rabbit IgG (H+L) antibodies (Jackson Immuno Research Laboratories Inc., West Grove, PA). The remaining cells were then transferred to a petri dish that had first been coated with affinity-purified goat anti-mouse IgM (μ chain) antibodies (Jackson Immuno Research Laboratories Inc., West Grove, PA) and second with anti-Thy-1.1 monoclonal IgM antibodies (cell line T11D7e2; number TIB-103, American Type Culture Collection, Manassas, VA). After repeatedly rinsing the plate with DPBS, the adherent RGCs were released by first incubating the cells in a 0.125% trypsin solution, and then by manually pipetting an enzyme inhibitor solution (30% FBS in Neurobasal-A) along the surface of the dish.
Purified RGCs were plated onto poly-D-lysine/laminin-coated Biocoat glass coverslips (12 mm round; BD Biosciences, Bedford, MA) in 24-well tissue culture plates at a density of 2.5x104 cells per well. The cells were cultured in 600 μl of serum-free culture medium consisting of Neurobasal-A with 2% B27 supplements, 1 mM glutamine, 50 ng/ml BDNF, 10 ng/ml CNTF, 5 mM forskolin, and 10 mg/ml gentamicin. Cultures were maintained at 37 °C in a humidified 5% CO2-air atmosphere. All experiments on the isolated RGCs were performed on the second day following cell dissociation and panning.
Electrophysiological recordings from isolated retinal ganglion cells
Whole-cell recordings of Ca2+ channel currents were obtained from individual RGCs in the purified culture using the ruptured-patch technique. The standard bath solution to isolate Ca2+ channel currents, using barium as a charge carrier, contained (in mM): 115 NaCl, 2.5 KCl, 5 CsCl, 10 BaCl2, 15 TEACl, 10 glucose, and 15 HEPES, adjusted to pH 7.6 with NaOH, while the intracellular pipette solution contained (in mM): 140 CsCl, 0.8 MgCl2, 0.1 CaCl2, 1:4 EGTA:CsOH, 10 HEPES, 1 Mg2+-ATP, and 0.2 Na+-GTP, adjusted to pH 7.2 with CsOH. Tetrodotoxin (TTX; 1 μM) was added to the bath solution in order to eliminate any contribution from sodium channels to the whole-cell current. WIN 55,212-2 was added to the superfusing standard bath solution, which was applied at room temperature (between 21 and 25 °C).
Patch electrodes were pulled from fire polished micro-hematocrit capillary tubes (VWR Scientific, West Chester, PA) using a two-step vertical pipette puller (Kopf model 730, David Kopf Instruments, Tujunga, CA). Pipette tips were first dipped in standard intracellular solutions and then back-filled with the same solution. Filled pipettes had 5-10 MΩ tip resistances, measured in the standard bath. The bath reference electrode consisted of a bath solution-filled agar bridge with an AgCl wire (World Precision Instruments, Sarasota, FL). Offset currents were nulled before seals were made. Whole-cell voltage was clamped with an Axopatch-1D amplifier (Axon Instruments, Foster City, CA) using whole-cell capacitance and series resistance compensation to reduce capacitive artifacts. The current signal was filtered at 0.5-1 kHz (Ithaco 4302 Dual 24dB/octave filter, Ithaca, NY) and digitized at 1 kHz with an Indec Systems interface (Sunnyvale, CA) for storage on the hard disk of a computer running BASIC-FASTLAB acquisition software. BASIC-FASTLAB generated the voltage-clamp commands, and provided some data analysis. Holding potential was set at -60 mV to isolate high-voltage activated Ca2+ channel activity, and voltage steps in 10 mV increments of 100 ms duration from -70 mV to +40 mV were applied every 1 s. Current-voltage (I-V) relations were constructed by calculating the mean current about 10 ms before the end of each voltage step.
All data are reported as the means±SEM and statistical analysis was performed using SigmaStat software (SigmaStat 2.03; SPSS Science, Chicago, IL). For the electrophysiology experiments, statistical analyses of drug effect were performed on raw data using Student's paired t-tests. Differences between mean current remaining from two different samples were compared with the non-parametric Mann-Whitney Rank Sum Test. Probability (p) values of less than 0.05 were considered statistically significant (* p<0.05).
CB1Rs in the rat retina and in cultured retinal ganglion cells
RT-PCR with cDNA templates from rat retina and purified cultured RGCs resulted in a PCR product of the expected size (521 bp) for the CB1 receptor (Figure 1A). Subsequent sequencing of the PCR product confirmed that the sequence of the PCR product corresponded to the sequence for the rat CB1 receptor (GenBank number NM_012784).
Immunocytochemical staining of purified cultured RGCs with CB1R antibodies showed localization of CB1R protein in isolated RGCs, with punctate labeling seen throughout the cell soma area and neurites (Figure 1B). Staining for CB1Rs was suppressed by antibody preabsorption with the peptide antigen (Figure 1C).
CB1R-mediated inhibition of HVA Ca2+ channel currents in retinal ganglion cells
The effect of CB1R agonist, WIN 55,212-2, on high voltage-activated (HVA) Ca2+ channel activity was assessed under voltage clamp in purified rat RGCs. A holding potential of -60 mV was used to inactivate low-voltage-activated Ca2+ channels and isolate HVA Ca2+ channels. When tested in 10 mM Ba2+ solution, RGC Ca2+ channel currents, which were completely blocked by cadmium (100 μM, -0.2±0.8% remaining; n=12; data not shown), were significantly inhibited by 5 μM WIN 55,212-2 (p<0.05; Figure 2). The time course of the drug application (Figure 2A) demonstrates that the Ca2+ channel currents decrease after 2 min of WIN 55,212-2 superfusion, and that this inhibition was generally not reversible after 4 min of washing. Following WIN 55,212-2 superfusion, current inhibition could be recovered in only 2 of 5 cells, possibly reflecting the lipophilic nature of the cannabinoid agonist. Figure 2B shows sample current traces elicited by a depolarizing voltage step to 0 mV from a holding potential of -60 mV with the inhibition by WIN 55,212-2 (WIN, 5 μM) evident. Current-voltage relations generated from the same cell show that WIN 55,212-2 reduced the amplitude of HVA Ca2+ channel currents with no apparent voltage dependence (Figure 2C).
The Ca2+ channel current inhibition seen in the presence of 5 μM WIN 55,212-2 was blocked by both CB1R antagonists, AM281 and SR141716. The time course of WIN application during superfusion with SR141716 (0.1 μM; SR) in Figure 3A shows no effect of WIN in this cell. Figure 3B shows sample current traces elicited by a depolarizing voltage step to 0 mV from a holding potential of -60 mV with no apparent inhibition by WIN 55,212-2 (5 mM). Current-voltage (I-V) relations generated from the same cell show that in the presence of SR141716, WIN 55,212-2 had no effect on the amplitude or voltage dependence of HVA Ca2+ channel currents (Figure 3C).
Data summarized in Figure 4 indicate that HVA Ca2+ channel current in RGCs was significantly (p<0.05) reduced by 20±6% (n=5), 25±6% (n=4), and 51±9% (n=5) in the presence of 0.5, 1, and 5 μM WIN 55,212-2, respectively. The inhibition caused by 5 μM WIN 55,212-2 was blocked by CB1R antagonists, AM281 (0.1 μM, 83±7% remaining, n=4) and SR141716 (0.1 μm, 95±9% remaining, n=5).
Our results demonstrate the presence of CB1R mRNA in purified RGC cultures. CB1R protein in isolated RGCs was also confirmed by positive labeling using a CB1R antibody. Patch-clamp recordings showed that voltage-gated Ca2+ channel currents in isolated rat RGCs are inhibited in a dose-dependent manner by the CB1R agonist, WIN 55,212-2. This inhibition was blocked by the CB1R antagonists AM281 and SR141716. Taken together, these results further establish the presence of CB1Rs in RGCs and show that cannabinoids activate signaling pathways leading to inhibition of HVA Ca2+ channels in these cells.
In the retinas of monkey, rat, mouse, chick and salamander, CB1R immunoreactivity has been identified in both outer and inner plexiform layers, the inner nuclear layer and the ganglion cell layer [24,30]. In fish retina, CB1R immunoreactivity was also seen in Müller cells and while labeling was present in bipolar cells it was absent in the ganglion cells [24,31]. The wide distribution of cannabinoid receptors in the vertebrate retina suggest that an endocannabinoid system may be of functional importance in the regulation of retinal activity and the processing of visual signals. In accordance with this, the endogenous receptor ligands, anandamide and 2-AG have been detected in the mammalian retina [24,32-34] together with AEA synthetase and hydrolase activity [32,33]. Fatty acid amide hydrolase (FAAH), the microsomal enzyme that hydrolyses the endocannabinoid anandamide to arachidonic acid and ethanolamine, as well as 2-AG, has also been described in rat RGCs . Thus, endogenous cannabinoid ligands, released from retinal neurons, may function as neurotransmitters and neuromodulators to activate cannabinoid receptors and modulate retinal function.
Activation of CB1Rs in the retina has been reported to have a number of physiological actions. The cannabinoid receptor agonist, WIN 55212-2 was reported to inhibit K+ currents in salamander photoreceptors, while it enhanced the Ca2+ currents of rod photoreceptors and suppressed Ca2+ currents of large single cones in this species . These differential effects of CB1R activation in salamander rods and cones may be attributable to the presence of different L-type Ca2+ channel α subunits. In goldfish cones, however, biphasic modulation of Ca2+, K+ and Cl currents was observed with WIN 55212-2 . Low doses of the cannabinoid agonist (<1 μM) enhanced currents via a cholera toxin-sensitive Gs pathway, and higher doses of WIN 55212-2 acting via pertussis toxin (PTX)-sensitive Gi/o pathway, inhibited these currents. These effects were all blocked by the CB1R antagonist, SR141716A. Thus, the biphasic effects of WIN 55212-2 in goldfish cones were attributed to the coupling of CB1Rs to two distinct signal transduction pathways with different efficiencies, as has been previously reported for other G protein coupled receptors, including β2- and α2-adrenoreceptors [37,38]. In salamander bipolar cells, CB1R activation did not produce an enhancement of L-type Ca2+ current, rather Ca2+ channel currents were inhibited . In other cell types of the CNS, activation of CB1Rs results in inhibition of N- and P/Q-type Ca2+ channels [19,39,40]. Suppression of N-type Ca2+ channel currents following CB1R activation has been reported to occur via a PTX-sensitive Gi/o-coupled pathway that is independent of cAMP metabolism [15,16].
At many central synapses, the release of endocannabinoids by postsynaptic cells provides a rapid retrograde signal that activates presynaptic CB1Rs, decreases presynaptic Ca2+ influx and inhibits neurotransmitter release [3,4,18,40,41]. In the retina, CB1Rs have previously been identified at several sites including rod and cone photoreceptors and bipolar cells. The inhibition of presynaptic Ca2+ and K+ channels in these cells would be expected to modulate synaptic transmission and alter visual processing. For example, in photoreceptors, CB1R-mediated inhibition of Ca2+ channels would reduce the amplitude of synaptic signals and subsequently reduce signal strength propagated throughout the retina. In contrast, facilitation of Ca2+ channels, as reported at lower concentration of WIN 55212-2 in goldfish cones  and in salamander rods  would strengthen signaling at subsequent levels of retinal processing. Inhibition of K+ current in photoreceptors by CB1R activation in photoreceptors would be expected to depolarize the cells, offsetting the effects of Ca2+ channel inhibition. Inhibition of K channels might also alter the temporal response properties of photoreceptors.
Since RGCs carry the output of the retina, our data could imply that endocannabinoids, released in a Ca2+-dependent manner from presynaptic neurons and/or from RGCs themselves, can act to inhibit RGC somatic or dendritic HVA Ca2+ channels and subsequently modulate postsynaptic integrative processing. Alternatively, it is possible that in these purified cultures of RGCs, CB1Rs that are normally expressed presynaptically at the axon terminals of RGCs projecting into the brain, find expression throughout the soma and neuritic processes of the cultured cells. The presence of atypical cannabinoid receptors (for review see ) or binding to other non-cannabinoid receptors could also contribute to the postsynaptic actions of cannabinoid ligands . However, as SR141716A and AM281, both selective CB1R antagonists [43-45], abrogated the inhibitory effects of WIN 55,212-2 on Ca2+ currents in RGCs, this would argue for a CB1R -mediated effect.
Rat RGCs have been reported to express several different types of HVA Ca2+ channel, including ω-conotoxin-sensitive N-type (40-50%), nifedipine-sensitive L-type (15-30%), but not ω-agatoxin-sensitive P/Q type [46-49]. In RGCs, inhibition of HVA Ca2+ channels would be expected to alter all Ca2+-sensitive responses of the cells, including activation of Ca2+-sensitive ion channels, Ca2+-mediated neurotransmitter release, and other Ca2+-regulated processes.
We thank Mr. Jianing Yu and Drs. Andrew Hartwick and William Baldridge of the Department of Anatomy & Neurobiology at Dalhousie University for providing the purified cultures of retinal ganglion cells. This work was supported by grants from the Canadian Institutes for Health Research (CIHR; MT-10968 to SB; IAO-13484 to MEMK; MGC-57078 to SB, MEMK, and others). MRL was supported by CIHR/CNIB E.A. Baker Studentship Award.
1. Di Marzo V, De Petrocellis L, Fezza F, Ligresti A, Bisogno T. Anandamide receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66:377-91.
2. Pertwee RG, Ross RA. Cannabinoid receptors and their ligands. Prostaglandins Leukot Essent Fatty Acids 2002; 66:101-21.
3. Fride E. Endocannabinoids in the central nervous system: from neuronal networks to behavior. Curr Drug Targets CNS Neurol Disord 2005; 4:633-42.
4. Piomelli D. The molecular logic of endocannabinoid signalling. Nat Rev Neurosci 2003; 4:873-84.
5. Begg M, Pacher P, Batkai S, Osei-Hyiaman D, Offertaler L, Mo FM, Liu J, Kunos G. Evidence for novel cannabinoid receptors. Pharmacol Ther 2005; 106:133-45.
6. Lutz B. Molecular biology of cannabinoid receptors. Prostaglandins Leukot Essent Fatty Acids 2002; 66:123-42.
7. Ashton JC, Friberg D, Darlington CL, Smith PF. Expression of the cannabinoid CB2 receptor in the rat cerebellum: an immunohistochemical study. Neurosci Lett 2006; 396:113-6.
8. Van Sickle MD, Duncan M, Kingsley PJ, Mouihate A, Urbani P, Mackie K, Stella N, Makriyannis A, Piomelli D, Davison JS, Marnett LJ, Di Marzo V, Pittman QJ, Patel KD, Sharkey KA. Identification and functional characterization of brainstem cannabinoid CB2 receptors. Science 2005; 310:329-32.
9. Zhong L, Geng L, Njie Y, Feng W, Song ZH. CB2 cannabinoid receptors in trabecular meshwork cells mediate JWH015-induced enhancement of aqueous humor outflow facility. Invest Ophthalmol Vis Sci 2005; 46:1988-92.
10. Lu Q, Straiker A, Lu Q, Maguire G. Expression of CB2 cannabinoid receptor mRNA in adult rat retina. Vis Neurosci 2000; 17:91-5.
11. Abadji V, Lucas-Lenard JM, Chin C, Kendall DA. Involvement of the carboxyl terminus of the third intracellular loop of the cannabinoid CB1 receptor in constitutive activation of Gs. J Neurochem 1999; 72:2032-8.
12. Lauckner JE, Hille B, Mackie K. The cannabinoid agonist WIN55,212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc Natl Acad Sci U S A 2005; 102:19144-9.
13. Howlett AC, Fleming RM. Cannabinoid inhibition of adenylate cyclase. Pharmacology of the response in neuroblastoma cell membranes. Mol Pharmacol 1984; 26:532-8.
14. He JC, Gomes I, Nguyen T, Jayaram G, Ram PT, Devi LA, Iyengar R. The G alpha(o/i)-coupled cannabinoid receptor-mediated neurite outgrowth involves Rap regulation of Src and Stat3. J Biol Chem 2005; 280:33426-34.
15. Mackie K, Hille B. Cannabinoids inhibit N-type calcium channels in neuroblastoma-glioma cells. Proc Natl Acad Sci U S A 1992; 89:3825-9.
16. Caulfield MP, Brown DA. Cannabinoid receptor agonists inhibit Ca current in NG108-15 neuroblastoma cells via a pertussis toxin-sensitive mechanism. Br J Pharmacol 1992; 106:231-2.
17. Twitchell W, Brown S, Mackie K. Cannabinoids inhibit N- and P/Q-type calcium channels in cultured rat hippocampal neurons. J Neurophysiol 1997; 78:43-50.
18. Wilson RI, Nicoll RA. Endogenous cannabinoids mediate retrograde signalling at hippocampal synapses. Nature 2001; 410:588-92. Erratum in: Nature 2001; 411:974.
19. Guo J, Ikeda SR. Coupling of metabotropic glutamate receptor 8 to N-type Ca2+ channels in rat sympathetic neurons. Mol Pharmacol 2005; 67:1840-51.
20. Hampson AJ, Bornheim LM, Scanziani M, Yost CS, Gray AT, Hansen BM, Leonoudakis DJ, Bickler PE. Dual effects of anandamide on NMDA receptor-mediated responses and neurotransmission. J Neurochem 1998; 70:671-6.
21. Huang CC, Lo SW, Hsu KS. Presynaptic mechanisms underlying cannabinoid inhibition of excitatory synaptic transmission in rat striatal neurons. J Physiol 2001; 532:731-48.
22. Schlicker E, Kathmann M. Modulation of transmitter release via presynaptic cannabinoid receptors. Trends Pharmacol Sci 2001; 22:565-72.
23. Endoh T. Pharmacological characterization of inhibitory effects of postsynaptic opioid and cannabinoid receptors on calcium currents in neonatal rat nucleus tractus solitarius. Br J Pharmacol 2006; 147:391-401.
24. Straiker A, Stella N, Piomelli D, Mackie K, Karten HJ, Maguire G. Cannabinoid CB1 receptors and ligands in vertebrate retina: localization and function of an endogenous signaling system. Proc Natl Acad Sci U S A 1999; 96:14565-70.
25. Hirooka K, Bertolesi GE, Kelly ME, Denovan-Wright EM, Sun X, Hamid J, Zamponi GW, Juhasz AE, Haynes LW, Barnes S. T-Type calcium channel alpha1G and alpha1H subunits in human retinoblastoma cells and their loss after differentiation. J Neurophysiol 2002; 88:196-205.
26. Bertolesi GE, Shi C, Elbaum L, Jollimore C, Rozenberg G, Barnes S, Kelly ME. The Ca(2+) channel antagonists mibefradil and pimozide inhibit cell growth via different cytotoxic mechanisms. Mol Pharmacol 2002; 62:210-9.
27. Barres BA, Silverstein BE, Corey DP, Chun LL. Immunological, morphological, and electrophysiological variation among retinal ganglion cells purified by panning. Neuron 1988; 1:791-803.
28. Hartwick AT, Zhang X, Chauhan BC, Baldridge WH. Functional assessment of glutamate clearance mechanisms in a chronic rat glaucoma model using retinal ganglion cell calcium imaging. J Neurochem 2005; 94:794-807.
29. Hartwick AT, Lalonde MR, Barnes S, Baldridge WH. Adenosine A1-receptor modulation of glutamate-induced calcium influx in rat retinal ganglion cells. Invest Ophthalmol Vis Sci 2004; 45:3740-8.
30. Straiker AJ, Maguire G, Mackie K, Lindsey J. Localization of cannabinoid CB1 receptors in the human anterior eye and retina. Invest Ophthalmol Vis Sci 1999; 40:2442-8.
31. Yazulla S, Studholme KM, McIntosh HH, Fan SF. Cannabinoid receptors on goldfish retinal bipolar cells: electron-microscope immunocytochemistry and whole-cell recordings. Vis Neurosci 2000; 17:391-401.
32. Yazulla S, Studholme KM, McIntosh HH, Deutsch DG. Immunocytochemical localization of cannabinoid CB1 receptor and fatty acid amide hydrolase in rat retina. J Comp Neurol 1999; 415:80-90.
33. Bisogno T, Delton-Vandenbroucke I, Milone A, Lagarde M, Di Marzo V. Biosynthesis and inactivation of N-arachidonoylethanolamine (anandamide) and N-docosahexaenoylethanolamine in bovine retina. Arch Biochem Biophys 1999; 370:300-7.
34. Matsuda S, Kanemitsu N, Nakamura A, Mimura Y, Ueda N, Kurahashi Y, Yamamoto S. Metabolism of anandamide, an endogenous cannabinoid receptor ligand, in porcine ocular tissues. Exp Eye Res 1997; 64:707-11.
35. Straiker A, Sullivan JM. Cannabinoid receptor activation differentially modulates ion channels in photoreceptors of the tiger salamander. J Neurophysiol 2003; 89:2647-54.
36. Fan SF, Yazulla S. Biphasic modulation of voltage-dependent currents of retinal cones by cannabinoid CB1 receptor agonist WIN 55212-2. Vis Neurosci 2003; 20:177-88.
37. Cherfils J, Chabre M. Activation of G-protein Galpha subunits by receptors through Galpha-Gbeta and Galpha-Ggamma interactions. Trends Biochem Sci 2003; 28:13-7.
38. Xiao RP. Beta-adrenergic signaling in the heart: dual coupling of the beta2-adrenergic receptor to G(s) and G(i) proteins. Sci STKE 2001; 2001:RE15.
39. Khasabova IA, Harding-Rose C, Simone DA, Seybold VS. Differential effects of CB1 and opioid agonists on two populations of adult rat dorsal root ganglion neurons. J Neurosci 2004; 24:1744-53.
40. Godino MC, Torres M, Sanchez-Prieto J. Inhibition of N- and P/Q-type Ca2+ channels by cannabinoid receptors in single cerebrocortical nerve terminals. FEBS Lett 2005; 579:768-72.
41. Kreitzer AC. Neurotransmission: emerging roles of endocannabinoids. Curr Biol 2005; 15:R549-51.
42. Martin BR, Mechoulam R, Razdan RK. Discovery and characterization of endogenous cannabinoids. Life Sci 1999; 65:573-95.
43. Rinaldi-Carmona M, Barth F, Heaulme M, Alonso R, Shire D, Congy C, Soubrie P, Breliere JC, Le Fur G. Biochemical and pharmacological characterisation of SR141716A, the first potent and selective brain cannabinoid receptor antagonist. Life Sci 1995; 56:1941-7.
44. Barth F, Rinaldi-Carmona M. The development of cannabinoid antagonists. Curr Med Chem 1999; 6:745-55.
45. Pertwee RG. Inverse agonism and neutral antagonism at cannabinoid CB1 receptors. Life Sci 2005; 76:1307-24.
46. Schmid S, Guenther E. Developmental regulation of voltage-activated Na+ and Ca2+ currents in rat retinal ganglion cells. Neuroreport 1996; 7:677-81.
47. Schmid S, Guenther E. Voltage-activated calcium currents in rat retinal ganglion cells in situ: changes during prenatal and postnatal development. J Neurosci 1999; 19:3486-94.
48. Taschenberger H, Grantyn R. Several types of Ca2+ channels mediate glutamatergic synaptic responses to activation of single Thy-1-immunolabeled rat retinal ganglion neurons. J Neurosci 1995; 15:2240-54.
49. Karschin A, Lipton SA. Calcium channels in solitary retinal ganglion cells from post-natal rat. J Physiol 1989; 418:379-96.